The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois.
Scott Olson | Getty Images
Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival.
Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. As the company proceeds with the trials needed to bring its experimental obesity injection to the market in the coming years, it could see a few advantages.
Amgen’s drug, MariTide, is taken less frequently than Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, and may cause longer-lasting weight loss than the market leaders’ injections. Amgen, one of the nation’s biggest pharmaceutical companies, can also produce drugs at scale – a huge edge over smaller…
